Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 12, 2009

BioLegend to Offer Services Based on PerkinElmer’s AlphaLISA Assay Technology

  • PerkinElmer and BioLegend entered an agreement that allows BioLegend to offer immunoassay development and bioanalytical testing based on PerkinElmer’s AlphaLISA® assay technology. Homogenous bead-based AlphaLISA comprises highly sensitive and quantitative assays with broader dynamic ranges than standard ELISAs, according to PerkinElmer.

    Furthermore, the advantages of AlphaLISA technology allow for easy integration into automated high-throughput testing systems, the firm adds. “The future of high-throughput assays lies in an increased need for automation,” notes Brad Kraft, president of BioLegend.

    “Many current immunological assay platforms have major drawbacks when it comes to meeting requirements for automation in the lab. We feel this collaboration with PerkinElmer is therefore a timely and highly promising advance that gives researchers greater understanding of basic disease biology and pathobiology, particularly when applied to biomarker assays.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »